Exozymes (EXOZ) Common Equity (2023 - 2024)
Exozymes (EXOZ) has disclosed Common Equity for 2 consecutive years, with -$3.6 million as the latest value for Q3 2024.
- Quarterly Common Equity fell 693.16% to -$3.6 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was -$3.6 million through Sep 2024, down 693.16% year-over-year, with the annual reading at -$384319.0 for FY2023, N/A changed from the prior year.
- Common Equity for Q3 2024 was -$3.6 million at Exozymes, down from -$2.3 million in the prior quarter.
- The five-year high for Common Equity was $607141.0 in Q3 2023, with the low at -$3.6 million in Q3 2024.